Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olmesartan medoxomil/amlodipine/hydrochlorothiazide - Daiichi Sankyo

Drug Profile

Olmesartan medoxomil/amlodipine/hydrochlorothiazide - Daiichi Sankyo

Alternative Names: CS-8635; Sevikar HCT; Sevikar Plus; Tribenzor

Latest Information Update: 10 Jan 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daewoong Pharmaceutical; Daiichi Sankyo Company
  • Class Antihypertensives; Benzothiadiazines; Dihydropyridines; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 10 Jan 2019 Chemical structure information added
  • 31 Dec 2018 Sungkyunkwan University School of Medicine and Daiichi Sankyo completes the phase III trial in Hypertension in South Korea (PO) (ISRCTN51756760)
  • 19 Mar 2018 Sungkyunkwan University School of Medicine and Daiichi Sankyo re-initiate a phase III for Hypertension in South Korea (ISRCTN51756760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top